Arcus Biosciences (RCUS) Shares Outstanding (Weighted Average) (2017 - 2025)
Arcus Biosciences has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $107.4 million for Q4 2025.
- Quarterly results put Shares Outstanding (Weighted Average) at $107.4 million for Q4 2025, up 19.2% from a year ago — trailing twelve months through Dec 2025 was $107.4 million (up 19.2% YoY), and the annual figure for FY2025 was $107.4 million, up 19.2%.
- Shares Outstanding (Weighted Average) for Q4 2025 was $107.4 million at Arcus Biosciences, up from $103.7 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for RCUS hit a ceiling of $107.4 million in Q4 2025 and a floor of $68.5 million in Q1 2021.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $73.6 million (2023), compared with a mean of $81.6 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 54.64% in 2021 and later rose 0.57% in 2022.
- Arcus Biosciences' Shares Outstanding (Weighted Average) stood at $69.3 million in 2021, then increased by 3.9% to $72.0 million in 2022, then grew by 2.78% to $74.0 million in 2023, then increased by 21.76% to $90.1 million in 2024, then grew by 19.2% to $107.4 million in 2025.
- The last three reported values for Shares Outstanding (Weighted Average) were $107.4 million (Q4 2025), $103.7 million (Q3 2025), and $106.1 million (Q2 2025) per Business Quant data.